Evidence map›Paper›PMID 38138972›Full record

ArticleInternational journal of molecular sciences2023

Anti-Tuberculosis Potential of OJT008 against Active and Multi-Drug-Resistant Mycobacterium Tuberculosis: In Silico and In Vitro Inhibition of Methionine Aminopeptidase.

Collins Onyenaka, Kehinde A Idowu, Ngan P Ha, Edward A Graviss, Omonike A Olaleye

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Collins OnyenakaDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA.
Kehinde A IdowuDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA.
Ngan P HaCenter for Infectious Disease Research, Houston Methodist Research Institute, Houston, TX 77030, USA.
Edward A GravissCenter for Infectious Disease Research, Houston Methodist Research Institute, Houston, TX 77030, USA.
Omonike A OlaleyeDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX 77004, USA.
Houston Methodist · USTexas Southern University · US

Funding

Targeted Nano-drug-delivery-systems of Frist-in-class Drugs for CRPC: PK/PD Evaluation and Combination TherapyU54MD007605 · NIMHD · TEXAS SOUTHERN UNIVERSITY · PI Dong Liang, Huan Xie · 2020 to 2026
$22.0M
NIH HHS U54MD007605NIMHD NIH HHS U54 MD007605
6 · The paper itself

Abstract

Despite the recent progress in the diagnosis of tuberculosis (TB), the chemotherapeutic management of TB continues to be challenging.

Indexed as

Mycobacterium tuberculosisTuberculosisTuberculosis, Multidrug-ResistantAminopeptidasesAntitubercular AgentsCobaltHumansMetalsMethionyl AminopeptidasesNickelAminopeptidasesAntitubercular AgentsCobaltMetalsMethionyl AminopeptidasesNickelmethionine aminopeptidase (MetAP)Mycobacterium tuberculosisN-terminal methionine excision (NME)tuberculosis

Identifiers

PMID38138972
PMCPMC10742973
OpenAlexW4389362749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.